Verastem shares surge more than 50% after pancreatic-cancer treatment study data

"Target joins Walmart in pulling back on DEI. But this big retailer and its shareholders…" - Read more, market watch: January 24, 2025 |
"BMW Motorrad enjoyed its best-ever year of sales in 2024" - Read more, New Atlas: January 24, 2025 |
"Trump tariff talk is heating up on Wall Street, signaling a rocky road ahead for…" - Read more, market watch: January 24, 2025 |
"Trump says there are bigger China threats than TikTok. Here’s where he could be going…" - Read more, market watch: January 24, 2025 |
"Space-sector IPOs set to take off as industry braces for a busy 2025" - Read more, market watch: January 24, 2025 |
"Vanguard’s U.S. stock-market call is even more shocking than you realize" - Read more, market watch: January 24, 2025 |
"LNG exporter Venture Global dips below IPO price in its trading debut" - Read more, market watch: January 24, 2025 |
"2-year Treasury yield ends at lowest level in a week as Fed meeting shifts into…" - Read more, market watch: January 24, 2025 |
"How Visa and other fintech stocks can get a boost from AI" - Read more, market watch: January 24, 2025 |
"This restaurant stock that tripled in 2024 just got downgraded ahead of earnings" - Read more, market watch: January 24, 2025 |

Verastem shares surge more than 50% after pancreatic-cancer treatment study data

By: market watch Posted On: May 23, 2024 View: 46

[unable to retrieve full-text content]

Shares of Verastem rose late Thursday after interim data from the company’s trial evaluating a combination therapies to treat pancreatic cancer showed a high overall response rate.

Read this on market watch Header Banner

Contact Us

Contact Form

About

Brainfind is your one-stop shop for breaking news headlines and personalized news stories. Not only are we a news aggregator and content curator, we also allow registered users to publish their own articles on our website with full credit and their social links.